6533b7d9fe1ef96bd126d74c

RESEARCH PRODUCT

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.

Norma C. GutiérrezLuzalba Sanoja-floresLuzalba Sanoja-floresBruno PaivaJosé-maría MoraledaJuan Flores-monteroJuan Flores-monteroLaura RosiñolLuis PalomeraJesús F. San-miguelMiguel-teodoro HernándezMaría-luisa Martín-ramosJacques J.m. Van DongenRafael Martínez-martínezMaria-victoria MateosJavier De La CruzJesús MartínAlbert OriolJavier De La RubiaJavier De La RubiaLourdes CordónMaría-belén VidrialesMaria-jose CalasanzJoan BargayAnna SuredaLucia Lopez-angladaNoemi PuigAlberto OrfaoAlberto OrfaoMaria-teresa CedenaRamón García-sanzIsabel KrsnikLeire BurgosM.j. BlanchardJuan José LahuertaRoberto MaldonadoJoaquin Martinez-lopezRafael RiosJoan Bladé

subject

OncologyMaleCancer Researchmedicine.medical_specialtyNeoplasm ResidualDiseaseResidualTHERAPYDexamethasoneFlow cytometryBortezomib03 medical and health sciences0302 clinical medicineInternal medicinehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansMeaning (existential)Longitudinal StudiesLenalidomideMultiple myeloma030304 developmental biologyCONSOLIDATIONRandomized Controlled Trials as Topic0303 health sciencesCOMPLETE RESPONSEmedicine.diagnostic_testbusiness.industryMiddle Agedmedicine.diseaseFlow Cytometry3. Good healthClinical trialPROGNOSTIC VALUEbody regionsMRDOncologyClinical Trials Phase III as Topic030220 oncology & carcinogenesisFemaleSTEM-CELL TRANSPLANTbusinessMultiple MyelomaDARATUMUMAB

description

[Purpose] Assessing measurable residual disease (MRD) has become standard with many tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain, particularly when assessed by next-generation flow (NGF) cytometry. Thus, we aimed to determine the applicability and sensitivity of the flow MRD-negative criterion defined by the International Myeloma Working Group (IMWG).

10.1200/jco.19.01231https://pubmed.ncbi.nlm.nih.gov/31770060